Loading clinical trials...

The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry

NCT00766948•Scripps Translational Science Institute

Summary

By creating a neurogenebank from Parkinson's disease patients' blood donations we will ultimately be able to define genes for Parkinson's disease and other neurological conditions.

Eligibility

Age

30 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Is age 30 years or older at the time of onset of Parkinson's
•Has been diagnosed with idiopathic Parkinson's Disease by a Scripps Neurologist
•Is reliable, cooperative and willing to comply with all protocol-specified procedures and/or sub-study if consented or have legal representative/guardian willing to do so
•Able to understand and grant informed consent or have a legal representative/ guardian who is able to do so

Exclusion Criteria

•Patient has been previously enrolled in The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry
•If a blood draw would be contraindicated for any reason
•Has a significant chronic medical condition (i.e. CVA, hepatic encephalopathy) which, in the investigator's option, may interfere with the patient's optimal participation in the study
•Treatment with any investigational agents or devices within 30 days preceding enrollment in the study
•Has undergone ECT within 90 days preceding enrollment in the study

Locations (3)

Scripps Clinic, Torrey Pines

La Jolla, California, United States

Scripps Translational Science Institute

La Jolla, California, United States

The Scripps Research Institute

La Jolla, California, United States

Key Dates

Start Date

August 1, 2008

Primary Completion Date

August 1, 2030

Completion Date

August 1, 2030

Last Updated

January 16, 2025

Enrollment

100

ESTIMATED participants

Conditions

Parkinson's Disease

Interventions

There is no intervention, this is a biorepository.

OTHER

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611

Parkinson's Disease

View study

RECRUITINGPHASE1

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGNA

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 16, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry

Inclusion Criteria

Exclusion Criteria

Deep Brain Stimulation Therapy in Movement Disorders

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations